Treatments

*September 2020* New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers…

*October 2020* Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level. The molecular landscape of non–small cell lung cancer (NSCLC), especially with EGFR mutations and acquired resistance, continues to get more complex as preliminary…

*October 2020* Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD, MPH.​ “It’s important to understand that there is now another option…

*October 2020* — Similar survival and less cognitive decline compared with conventional WBRT Stereotactic radiosurgery (SRS) for cancer patients with four to 15 brain metastases staved off cognitive decline better than conventional whole-brain radiation therapy (WBRT), while yielding similar survival outcomes, a randomized trial found. For the primary endpoint of…

*November 2020* Watch the EGFR Research Summit wrap up video. You can learn more at our EGFR Summit website – www.egfrsummit.com 

*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi. According to data from the phase 2 DESTINY-Lung01 trial, trastuzumab deruxtecan induced a confirmed objective response rate of…

*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses were seen in all patients regardless of how many previous drugs…

*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC). A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in…